Back to News
Market Impact: 0.12
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Can-Fite BioPharma said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma. The update does not include efficacy, safety, or timeline specifics, so near-term read-through for outcomes appears limited.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
CANF0.05
More News
- Apple makes biggest change to iPhone release cadence in 7 years in Ternus' first showcase as CEO
- What Wall Street thought of Apple's foldable iPhone and what the Duo means for the stock
- Trump’s ‘Big Beautiful Bill’ projected to add a big, unbeautiful $3.4 trillion to the national debt over the next decade
- Chinese car exports are increasingly flooding the world despite all of the west’s (mixed) efforts to keep them out
- Defense tech Mach Industries doubles valuation to $3.7B in 3 months
- Macy's posts strong results, raises guidance as turnaround begins to take hold